Passage BIO, Inc. files 425

— Passage Bio is acquiring Remix Therapeutics in an all-stock merger. The deal structure results in pre-merger Passage Bio shareholders owning approximately 7% of the combined company and pre-merger Remix shareholders (including private placement investors) owning approximately 93%. The expected closing is in the fourth quarter of 2026. (2) DEAL TERMS —